- TheStreet.com•51 minutes ago
Actelion shares led Zurich stocks higher Monday despite the company's admission that its potential blockbuster Opsumit drug failed to meet a key target in late-stage trials.
- Investopedia•2 hours ago
Having beaten Wall Street's earnings estimates in twelve straight quarters, JNJ has maintained its growth momentum in the face of competitive pressure.
- Reuters•3 hours ago
Actelion's Opsumit drug missed the main target in a late-stage study of patients with pulmonary arterial hypertension due to Eisenmenger Syndrome, the Swiss drugmaker said on Monday. Actelion had been conducting the Phase III trial on 226 patients as part of its push to expand clinical use of Opsumit -- its follow-on medicine to blockbuster PAH drug Tracleer that has lost patent protection -- for patients suffering from different forms of the deadly heart-lung ailment.
JNJ : Summary for Johnson & Johnson Common Stock - Yahoo Finance
Johnson & Johnson (JNJ)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||114.08 - 115.03|
|52 Week Range||96.04 - 126.07|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||20.04|
|Dividend & Yield||3.20 (2.80%)|
|1y Target Est||N/A|